



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## SX 011

<b>Cat. No.:</b>	HY-108646		
<b>CAS No.:</b>	309913-42-6		
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>27</sub> ClFN <sub>3</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	483.96		
<b>Target:</b>	p38 MAPK; JNK		
<b>Pathway:</b>	MAPK/ERK Pathway		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 100 mg/mL (206.63 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
<b>Preparing Stock Solutions</b>	1 mM	2.0663 mL	10.3314 mL	20.6629 mL
	5 mM	0.4133 mL	2.0663 mL	4.1326 mL
	10 mM	0.2066 mL	1.0331 mL	2.0663 mL
Please refer to the solubility information to select the appropriate solvent.				
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (5.17 mM); Clear solution</li> </ol>			

## BIOLOGICAL ACTIVITY

<b>Description</b>	SX 011 is a p38 inhibitor with IC <sub>50</sub> s of 9 nM and 90 nM against p38α and p38β, respectively. SX 011 also inhibits JNK-2 with an IC <sub>50</sub> of 100 nM. SX-011 is orally bioavailable <sup>[1]</sup> .			
<b>IC<sub>50</sub> &amp; Target</b>	p38α 9 nM (IC <sub>50</sub> )	p38β 90 nM (IC <sub>50</sub> )	p38δ > 300,000 nM (IC <sub>50</sub> )	p38γ > 300,000 nM (IC <sub>50</sub> )
	JNK2 100 nM (IC <sub>50</sub> )	JNK1 > 300,000 nM (IC <sub>50</sub> )		

---

<b>In Vitro</b>	<p>SX-011 inhibits LPS stimulated TNF<math>\alpha</math> and interleukin-1<math>\beta</math> (IL-1<math>\beta</math>) from human peripheral blood mononuclear cells (PBMC) with an IC<sub>50</sub> of 200 nM and 900 nM, respectively. Additionally, IL-6 (IC<sub>50</sub> 250 nM) and IL-8 (IC<sub>50</sub> 100 nM) are significantly inhibited in this assay<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
<b>In Vivo</b>	<p>SX-011 is orally bioavailable in preclinical species (rat, 24%; monkey, 29%; dog, 43%) and has demonstrated efficacy in both acute and chronic models of inflammation in rats. Rat t<sub>1/2</sub> = 30 min<sup>[1][2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

---

## REFERENCES

[1]. Lee MR, et al. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. *Curr Med Chem*. 2005;12(25):2979-94.

[2]. Hynes J Jr, et al. Small molecule p38 inhibitors: novel structural features and advances from 2002-2005. *Curr Top Med Chem*. 2005;5(10):967-85.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA